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Metabolic reprogramming of myeloid-derived suppressive cells
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Recent studies indicate that not only cancer cells 
go through metabolic reprogramming, immune cells also 
have distinct metabolic characteristics to influence their 
functions [1]. Myeloid-derived suppressor cells (MDSCs) 
critically contribute to tumorigenesis in three major ways. 
Firstly, MDSCs directly stimulate tumor cell proliferation, 
growth and metastasis; Secondly, MDSCs alter ECs’ 
functions by influencing angiogenesis, tube formation, 
proliferation and permeability to facilitate MDSCs and 
cancer cell penetration across the vascular wall. Thirdly, 
MDSCs change organization of the thymus and spleen, 
impair progression of T cell development in the thymus, 
retard T cell maturation in the spleen, and weaken anti-
tumor immune surveillance. These pathological functions 
are harnessed by the fatty acid metabolic pathway 
controlled by lysosomal acid lipase (LAL) [2–4].
Fatty acid metabolism is required for cell 
biosynthesis and bioenergetics of cell proliferation and 
survival. Mitochondrial fatty acid oxidation produces 
more than twice as much ATP per mole as oxidation of 
glucose or amino acids [5]. In fat catabolism, triglycerides 
and cholesteryl esters are hydrolyzed into fatty acids and 
cholesterol by LAL in lysosomes. Fatty acids are further 
broken down through a process known as beta oxidation 
that results in acetyl-CoA. Beta oxidation of fatty acids 
with an odd number of methylene bridges produces 
propionyl CoA, which is converted into succinyl-CoA 
and fed into the TCA cycle in the mitochondria. In the 
absence of the regular supply of fatty acids during LAL 
deficiency, the energy consumption is reprogrammed 
toward extracellular glucose consumption to fuel oxidative 
phosphorylation (OXPHOS). This was first observed 
by gene microarray analysis, in which expression of 
glycolytic metabolic genes was increased in LAL-deficient 
MDSCs [6]. Glycolysis breaks glucose (a six-carbon 
molecule) down into pyruvate (a three-carbon molecule). 
Pyruvate moves into mitochondria to be converted into 
acetyl-CoA by decarboxylation and enters the TCA 
cycle. In addition to glycolytic genes, gene expression 
of glucose transporters (GLUT3, GLUT6, GLUT8, 
GLUT12, and GLUT13) and the TCA cycle enzymes was 
also significantly increased in LAL-deficient MDSCs-like 
cells [7].
This metabolic reprogramming of energy 
consumption comes with penalties, very similar to cancer 
cells [6–8]. 1) In LAL-deficient MDSCs, the mitochondrial 
membrane potential was impaired in association with 
increased expression of respiratory chain proteins 
(including NADH dehydrogenases, cytochrome proteins, 
ATPases and mitochondrial ribosomal proteins), increased 
glycolysis and TCA metabolic rates, and increased ATP 
production; 2) LAL-deficient MDSCs showed increased 
expression of both lactate dehydrogenase A and B. In 
cancer cells, this altered metabolic process of aerobic 
glycolysis is advantageous to better survival; 3) ROS 
concentration was significantly increased in LAL-deficient 
MDSCs, accompanied with up-regulation of the nitric 
oxide/ROS production genes, glutathione peroxidase/
glutathione reductase genes, and glucose 6-phosphate 
dehydrogenase gene. High level of ROS allows for the 
stimulation of cell proliferation, induction of genetic 
instability, and evasion.
This fatty acid to glucose metabolic reprogramming 
is controlled by overactivation of PI3K/ thymoma viral 
proto-oncogene (AKT)/mammalian target of rapamycin 
(mTOR), a master regulator of metabolic switch in cells. 
This was first revealed by Ingenuity Pathway Analysis 
in association with altered expression of other genes 
involving cell growth, cell cycle entry, cell survival, 
cell migration, histone epigenetics, and bioenergetic 
pathways [6]. Inhibition of mTOR, Raptor, Rictor, and 
Akt1 by pharmacological inhibitors or siRNA interference 
suppressed stimulation of tumor proliferation, progression, 
metastasis, and reduced immunosuppressive function of 
LAL-deficient MDSCs. These were concomitant with 
reversal of LAL-deficient MDSCs development from bone 
marrow Lin- progenitor cells, ROS overproduction, and 
impairment of mitochondrial membrane potential [2, 4].
As a control center of signaling for metabolic 
reprogramming [9], lysosome genesis and trafficking 
is regulated by Rab7 GTPase protein, which belongs 
to a superfamily of small-molecular-weight GTPase 
known to regulate intracellular membrane trafficking 
from early to late endosomes and lysosomes. A physical 
protein-protein interaction between Rab7 GTPase and 
mTOR, and colocalization on lysosomes of myeloid 
cells were observed [10]. Knocking down overexpressed 
Rab7 GTPase reversed the altered lysosome/mTOR 
distribution, reduced over-activation of mTOR, decreased 
glucose consumption, decreased ROS over-production, 
and increased healthy mitochondria. Inhibition of 
Rab7 GTPase led to reduced LAL-deficient MDSCs 
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differentiation from bone marrow Lin- progenitor 
cells, reduced trans-endothelial migration, reversed 
immunosuppression and tumor stimulation [10].
Fatty acid metabolites serve as hormonal ligands 
for nuclear receptors, such as peroxisome proliferator-
activated receptor gamma (PPARγ). PPRAγ ligand 
treatment of LAL-deficient MDSCs was able to 
correct mTOR-associated malfunctions, and reversed 
immunosuppression and tumor stimulation [11]. When 
the PPARγ function is impaired by a dominant negative 
form of PPARγ (dnPPARγ) expressed in the myeloid-
specific cells of the c-fms-rtTA/(tetO)7-dnPPARγ 
bitransgenic mice, tumor growth and metastasis were 
enhanced. Bone marrow MDSCs isolated from these 
mice stimulated tumor cell proliferation and migration. 
Similar to LAL-deficient MDSCs, MDSCs with dnPPARγ 
overexpression showed increased transendothelial 
migration, overactivation of the mTOR pathway, and 
ROS over-production [11]. These results indicate that 
PPARγ mediates neutral lipid metabolic signaling 
controlled by LAL, which provides a mechanistic basis 
for clinically targeting MDSCs to reduce the risk of 
cancer proliferation, growth and metastasis.
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